<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00662545</url>
  </required_header>
  <id_info>
    <org_study_id>A109324</org_study_id>
    <secondary_id>AI463-162</secondary_id>
    <nct_id>NCT00662545</nct_id>
  </id_info>
  <brief_title>Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection</brief_title>
  <official_title>Entecavir Intensification for Persistent Hepatitis B Virus (HBV) Viremia in HIV-HBV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate HIV-HBV infected individuals who have evidence of HBV replication in
      the blood after taking 48 weeks of more of the HBV active medication tenofovir in combination
      with emtricitabine or lamivudine. Eligible participants will be randomized to receive 24
      weeks of entecavir (ETV) 1 mg versus continued standard of care antiretroviral therapy. After
      24 weeks, individuals on entecavir or who remain HBV viremic on standard of care will receive
      ETV o for an additional 24 weeks. The hypothesis is that intensification with entecavir will
      reduce HBV DNA at 24 weeks more than continued antiretroviral therapy without entecavir.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: This is a randomized, controlled pilot study of open-label entecavir for the
      treatment of persistent HBV viremia in HIV-HBV coinfected individuals who have failed to
      suppress HBV replication after 48 weeks on tenofovir containing therapy.

      Primary Objective: To evaluate the mean log reduction of HBV DNA with entecavir(ETV)
      intensification in comparison to continued standard therapy with tenofovir and
      lamivudine/emtricitabine at 24 weeks of therapy

      Study Population: HIV-HBV co-infected individuals with detectable HBV DNA after 48 weeks of
      therapy with tenofovir and lamivudine/emtricitabine whose HIV viremia is well controlled ( &lt;
      75 copies at time of enrollment)

      Treatment: Subjects will be randomized to continue with standard therapy or to receive
      intensification with 1 mg daily of open label entecavir for the 24 week duration of the
      study.

      Sample Size: 24 subjects will be enrolled.

      Duration 24 weeks of treatment

      Primary Endpoint: Mean log10 reduction of HBV DNA at 24 weeks of standard therapy vs.
      entecavir intensification.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatitis B Virus (HBV) DNA</measure>
    <time_frame>week 24</time_frame>
    <description>HBV DNA carries the genetic blueprint of the virus. How many HBV DNA &quot;particles&quot; or &quot;copies&quot; are found in the blood indicates how rapidly the virus is reproducing in the liver.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Permanent Discontinuation Due to Toxicity</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of New Hepatic Decompensation( Ascites, Variceal Hemorrhage, Encephalopathy)</measure>
    <time_frame>every 4 weeks for 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ALT Flares</measure>
    <time_frame>every 4 weeks for 24 weeks</time_frame>
    <description>ALT flare: sudden increase in blood level of alanine transaminase (ALT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV RNA &lt; 75 Copies/ml</measure>
    <time_frame>entry, week 12, and week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>HIV Infections</condition>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Entecavir 1 mg for 24 weeks in addition to continued standard of care antiretroviral therapy containing tenofovir in addition to emtricitabine or lamivudine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>continued standard of care antiretroviral therapy which will include tenofovir in addition to emtricitabine or lamivudine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir with continued standard of care antiretroviral therapy</intervention_name>
    <description>1 mg by mouth daily</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Baraclude, Tenofovir, Truvada, Viread, 3TC, FTC, Epivir, Emtriva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>continued standard of care with tenofovir in addition to emtricitabine or lamivudine</intervention_name>
    <description>continued standard of care with tenofovir in addition to emtricitabine or lamivudine</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Tenofovir, Truvada, Viread, 3TC, FTC, Epivir, Emtriva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability and willingness to provide written informed consent

          -  HIV infection, documented in patient medical record. Acceptable forms of documentation
             include positive HIV antibody or detectable HIV RNA.

          -  Chronic HBV infection, defined as HBsAg positivity. Both hepatitis B &quot;e&quot; antigen
             (HBeAg) positive and negative subjects will be eligible.

          -  Detectable HBV DNA ( &gt; 160 copies/ml) after 48 weeks of therapy with TDF in
             conjunction with either 3TC or FTC

          -  Compensated liver disease, defined as a Child-Pugh-Turcot(CPT) Score &lt;7 at the time of
             enrollment.

        Note: If Bilirubin in elevated, direct and indirect bilirubin levels will be evaluated. If
        only indirect bilirubin elevated, direct bilirubin will be used for CPT score. If BOTH
        direct and indirect bilirubin are elevated, total bilirubin will be used for the CPT score.

          -  Stable antiretroviral therapy with no changes in the prior 8 weeks due to
             antiretroviral failure. HIV therapy modification for reasons other than virologic
             failure and without change in the tenofovir(TDF), lamivudine(3TC) or
             emtricitabine(FTC) moiety of the antiretroviral therapy will be permitted. HIV therapy
             must include TDF in conjunction with 3TC or FTC, and at least one other anti-HIV
             agent.

          -  HIV RNA of &lt;75 copies/ml within 8 weeks of study enrollment.

          -  Estimated creatinine clearance by Cockcroft-Gault of ≥ 50 ml/min

          -  Serum alpha-fetoprotein (AFP) of ≤50 ng/ml within 8 weeks of study entry, or if
             elevated &gt; 50 ng/ml, an imaging study demonstrating no evidence of hepatic tumor
             within 8 weeks of enrollment.

          -  Female study volunteers must not participate in a conception process (e.g., active
             attempt to become pregnant). If participating in sexual activity that could lead to
             pregnancy, the female study volunteer must use the following forms of contraception
             while receiving study-specific medication(s) and for 30 days after stopping the
             medication. One of the following methods MUST be used appropriately:

               -  Condoms1 (male or female) with or without a spermicidal agent

               -  Diaphragm or cervical cap with spermicide

               -  intrauterine device(IUD)

               -  Hormonal-based method

                    1. Condoms are recommended because their appropriate use is the only
                       contraception method effective for preventing HIV transmission.

        Note: Subjects with concomitant Hepatitis C infection will be permitted to enroll.

        Exclusion Criteria:

          -  Allergy or sensitivity to study drug

          -  Pregnancy, breastfeeding or unwillingness/inability to adhere to contraceptive methods
             for the duration of the study

          -  Prisoners or subjects who are incarcerated.

          -  Evidence of malignancy that would make the subject, in the opinion of the
             investigator, unsuitable for the study. This includes any systemic antineoplastic or
             immunomodulatory treatment or radiation within 24 weeks prior to study entry or the
             expectation that such treatment will be needed at any time during the study.

          -  Receipt of systemic corticosteroids within 90 days prior to study entry (as this
             medication may increase HBV replication).

          -  Investigational anti-HIV agents will be allowed on a case-by-case basis with the
             approval of the protocol team.

          -  Active drug or alcohol use or dependence that, in the opinion of the investigator,
             would interfere with adherence to study requirements.

          -  Any active medical, psychiatric or social circumstance that in the opinion of the
             investigator puts the subject at potential risk from study participation or makes
             adherence to the study protocol unlikely.

          -  Receipt of the following drugs with anti-HBV activity within 90 days prior to study
             entry or anticipated receipt during the course of the study including: adefovir(ADV),
             telbivudine, alpha interferon, penciclovir (Denavir) (except if given for &lt; 4 weeks),
             famciclovir (Famvir), diaminopurine dioxolane (DAPD), clevudine (L-FMAU), thymosin
             alpha 1, ganciclovir (treatment limited to &lt; 7 days is acceptable) (Cytovene),
             L-deoxythymidine, and L-deoxythymidine compounds and other investigational agents with
             anti-HBV activity.

          -  Receipt of nephrotoxic drugs (e.g., aminoglycosides, amphotericin B, vancomycin,
             cidofovir [Vistide], foscarnet [Foscavir], cisplatin, intravenous pentamidine
             [Pentam], oral tacrolimus [Prograf], cyclosporine [Sandimmune]) or the competitor of
             renal excretion, probenecid (Benemid), within 8 weeks prior to study entry or expected
             use of these agents during the course of the study. (Topical tacrolimus is allowed.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne F Luetkemeyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HIV/AIDS Division, San Francisco General Hospital, University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco General HIV Clinical Trials Group</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Muñoz A, Thomas DL; Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002 Dec 14;360(9349):1921-6.</citation>
    <PMID>12493258</PMID>
  </reference>
  <reference>
    <citation>Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, Kirk O, Lundgren JD; EuroSIDA Group. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005 Mar 24;19(6):593-601.</citation>
    <PMID>15802978</PMID>
  </reference>
  <reference>
    <citation>Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, Degott C, Benhamou JP, Erlinger S, Valla D, Marcellin P. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology. 1999 Apr;29(4):1306-10.</citation>
    <PMID>10094979</PMID>
  </reference>
  <reference>
    <citation>Fattovich G, Rugge M, Brollo L, Pontisso P, Noventa F, Guido M, Alberti A, Realdi G. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology. 1986 Mar-Apr;6(2):167-72.</citation>
    <PMID>3957228</PMID>
  </reference>
  <reference>
    <citation>Hoofnagle JH, Shafritz DA, Popper H. Chronic type B hepatitis and the &quot;healthy&quot; HBsAg carrier state. Hepatology. 1987 Jul-Aug;7(4):758-63. Review.</citation>
    <PMID>3301618</PMID>
  </reference>
  <reference>
    <citation>Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, Shih WL, Kao JH, Chen DS, Chen CJ. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst. 2005 Feb 16;97(4):265-72.</citation>
    <PMID>15713961</PMID>
  </reference>
  <reference>
    <citation>Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol. 2006 Aug;101(8):1797-803. Epub 2006 Jun 30.</citation>
    <PMID>16817842</PMID>
  </reference>
  <reference>
    <citation>Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006 Jan 4;295(1):65-73.</citation>
    <PMID>16391218</PMID>
  </reference>
  <reference>
    <citation>Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004 Oct 7;351(15):1521-31.</citation>
    <PMID>15470215</PMID>
  </reference>
  <reference>
    <citation>Stephan C, Berger A, Carlebach A, Lutz T, Bickel M, Klauke S, Staszewski S, Stuermer M. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. J Antimicrob Chemother. 2005 Dec;56(6):1087-93. Epub 2005 Nov 3.</citation>
    <PMID>16269552</PMID>
  </reference>
  <reference>
    <citation>Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, Rozenbaum W, Le Teuff G, Trylesinski A, Piketty C; TECOVIR Study Group. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology. 2006 Mar;43(3):548-55.</citation>
    <PMID>16496322</PMID>
  </reference>
  <reference>
    <citation>Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, von Boemmel F, Hoffmann C, Rockstroh J, Stoehr A, Wolf E, Soriano V, Berger F, Berg T, Carlebach A, Schwarze-Zander C, Schürmann D, Jaeger H, Mauss S. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS. 2006 Oct 3;20(15):1951-4.</citation>
    <PMID>16988516</PMID>
  </reference>
  <reference>
    <citation>Sheldon J, Camino N, Rodés B, Bartholomeusz A, Kuiper M, Tacke F, Núñez M, Mauss S, Lutz T, Klausen G, Locarnini S, Soriano V. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther. 2005;10(6):727-34.</citation>
    <PMID>16218172</PMID>
  </reference>
  <reference>
    <citation>Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D; BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006 Mar 9;354(10):1001-10.</citation>
    <PMID>16525137</PMID>
  </reference>
  <reference>
    <citation>Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006 Mar 9;354(10):1011-20. Erratum in: N Engl J Med. 2006 Apr 27;354(17):1863.</citation>
    <PMID>16525138</PMID>
  </reference>
  <reference>
    <citation>Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, Boron-Kaczmarska A, Martin P, Goodman Z, Colonno R, Cross A, Denisky G, Kreter B, Hindes R; AI463026 BEHoLD Study Group. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006 Jun;130(7):2039-49.</citation>
    <PMID>16762627</PMID>
  </reference>
  <reference>
    <citation>McMahon MA, Jilek BL, Brennan TP, Shen L, Zhou Y, Wind-Rotolo M, Xing S, Bhat S, Hale B, Hegarty R, Chong CR, Liu JO, Siliciano RF, Thio CL. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med. 2007 Jun 21;356(25):2614-21.</citation>
    <PMID>17582071</PMID>
  </reference>
  <reference>
    <citation>Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med. 2003 Jan 9;348(2):177-8.</citation>
    <PMID>12519935</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2008</study_first_submitted>
  <study_first_submitted_qc>April 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2008</study_first_posted>
  <results_first_submitted>May 14, 2013</results_first_submitted>
  <results_first_submitted_qc>May 15, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2013</results_first_posted>
  <last_update_submitted>May 17, 2013</last_update_submitted>
  <last_update_submitted_qc>May 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Viremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>participants recruited from medical clinic, between 7/2008 and 6/2009and 20011</recruitment_details>
      <pre_assignment_details>Overall sample size was reduced to 10 due to difficulty in recruitment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Entecavir Intensification</title>
          <description>Entecavir 1 mg for 24 weeks in addition to continued standard of care antiretroviral therapy containing tenofovir in addition to emtricitabine or lamivudine</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care</title>
          <description>continued standard of care antiretroviral therapy which will include tenofovir in addition to emtricitabine or lamivudine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entecavir Intensification</title>
          <description>Entecavir 1 mg for 24 weeks in addition to continued standard of care antiretroviral therapy containing tenofovir in addition to emtricitabine or lamivudine</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care</title>
          <description>continued standard of care antiretroviral therapy which will include tenofovir in addition to emtricitabine or lamivudine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HBV DNA at enrollment</title>
          <description>hepatitis B DNA level</description>
          <units>log10 IU/ML</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.2" lower_limit="2.4" upper_limit="6.4"/>
                    <measurement group_id="B2" value="3.8" lower_limit="1.9" upper_limit="7.7"/>
                    <measurement group_id="B3" value="3.2" lower_limit="1.9" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hepatitis B Virus (HBV) DNA</title>
        <description>HBV DNA carries the genetic blueprint of the virus. How many HBV DNA “particles” or “copies” are found in the blood indicates how rapidly the virus is reproducing in the liver.</description>
        <time_frame>week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir Intensification</title>
            <description>Entecavir 1 mg for 24 weeks in addition to continued standard of care antiretroviral therapy containing tenofovir in addition to emtricitabine or lamivudine</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>continued standard of care antiretroviral therapy which will include tenofovir in addition to emtricitabine or lamivudine</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatitis B Virus (HBV) DNA</title>
          <description>HBV DNA carries the genetic blueprint of the virus. How many HBV DNA “particles” or “copies” are found in the blood indicates how rapidly the virus is reproducing in the liver.</description>
          <units>log 10 IU/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="0.8" upper_limit="2.41"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.8" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Permanent Discontinuation Due to Toxicity</title>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir Intensification</title>
            <description>Entecavir 1 mg for 24 weeks in addition to continued standard of care antiretroviral therapy containing tenofovir in addition to emtricitabine or lamivudine</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>continued standard of care antiretroviral therapy which will include tenofovir in addition to emtricitabine or lamivudine</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Permanent Discontinuation Due to Toxicity</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of New Hepatic Decompensation( Ascites, Variceal Hemorrhage, Encephalopathy)</title>
        <time_frame>every 4 weeks for 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir Intensification</title>
            <description>Entecavir 1 mg for 24 weeks in addition to continued standard of care antiretroviral therapy containing tenofovir in addition to emtricitabine or lamivudine</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>continued standard of care antiretroviral therapy which will include tenofovir in addition to emtricitabine or lamivudine</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of New Hepatic Decompensation( Ascites, Variceal Hemorrhage, Encephalopathy)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of ALT Flares</title>
        <description>ALT flare: sudden increase in blood level of alanine transaminase (ALT)</description>
        <time_frame>every 4 weeks for 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir Intensification</title>
            <description>Entecavir 1 mg for 24 weeks in addition to continued standard of care antiretroviral therapy containing tenofovir in addition to emtricitabine or lamivudine</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>continued standard of care antiretroviral therapy which will include tenofovir in addition to emtricitabine or lamivudine</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of ALT Flares</title>
          <description>ALT flare: sudden increase in blood level of alanine transaminase (ALT)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV RNA &lt; 75 Copies/ml</title>
        <time_frame>entry, week 12, and week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir Intensification</title>
            <description>Entecavir 1 mg for 24 weeks in addition to continued standard of care antiretroviral therapy containing tenofovir in addition to emtricitabine or lamivudine</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>continued standard of care antiretroviral therapy which will include tenofovir in addition to emtricitabine or lamivudine</description>
          </group>
        </group_list>
        <measure>
          <title>HIV RNA &lt; 75 Copies/ml</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Entecavir Intensification</title>
          <description>Entecavir 1 mg for 24 weeks in addition to continued standard of care antiretroviral therapy containing tenofovir in addition to emtricitabine or lamivudine</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care</title>
          <description>continued standard of care antiretroviral therapy which will include tenofovir in addition to emtricitabine or lamivudine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anne Luetkemeyer</name_or_title>
      <organization>UCSF SFGH</organization>
      <phone>415 476 4082 ext 130</phone>
      <email>aluetkemeyer@php.ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

